Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 13/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9733176 | 0.90 | TBXAS1 (1.00) | TBXAS1ALDH1A1TBXA2R | |
| SCHEMBL9732738 | 0.88 | TBXAS1 (0.77) | TBXAS1ALDH1A1POLBTBXA2RCYP19A1 | |
| SCHEMBL9733927 | 0.86 | TBXAS1 (1.00) | TBXAS1ALDH1A1TBXA2R | |
| SCHEMBL9709594 | 0.82 | TBXAS1 (0.54) | TBXAS1TBXA2R | |
| SCHEMBL9732565 | 0.80 | TBXAS1 (0.79) | TBXAS1ALDH1A1POLBTBXA2RCYP19A1 | |
| SCHEMBL10838285 | 0.79 | ALDH1A1 (0.71) | TBXAS1ALDH1A1POLBCYP19A1 | |
| SCHEMBL9732578 | 0.79 | TBXAS1 (0.83) | TBXAS1ALDH1A1TBXA2RCYP19A1 | |
| SCHEMBL9732801 | 0.79 | TBXAS1 (0.82) | TBXAS1TBXA2R | |
| SCHEMBL9709574 | 0.78 | TBXAS1 (0.54) | TBXAS1TBXA2R | |
| SCHEMBL10836309 | 0.78 | ALDH1A1 (0.70) | TBXAS1ALDH1A1POLBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5153214-A | Treating cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0493324-A1 | Certain (arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids and derivatives thereof | CIBA-GEIGY AG (CH) | 1992-07-01 | — | — | EP | disclosed |
| US-5025025-A | Cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1991-06-18 | — | — | US | disclosed |
| EP-0405391-A1 | Certain (arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids and derivatives thereof | CIBA-GEIGY AG (CH) | 1991-01-02 | — | — | EP | disclosed |